Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel ... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A randomised phase III trial of adjuvant cemiplimab in patients with resected stage II-IIIA NSCLC... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyro... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus A... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvan... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Open Label, Multiple-Dose Study to Assess the Changes in Cerebrospinal Fluid Biomarker... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'Evaluating the efficacy and safety of Platelet Rich Plasma for patients with Peyronie’s disease: ... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'SURFactant Administration by SUPraglottic Airway (the SURFSUP Trial)'. The following are the othe... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpa... Read More